Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia

• Status: Unknown status
• Trial end date: 2017-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Neutropenic fever is a life threatening condition that is not rare in patients suffering from hematologic disorders, and of paramount importance to early and effective treatment. In this trial we concentrate on hospitalized patients with hematologic malignancies who develop neutropenic fever.

In recent years, several studies were conducted to examine possible changes in the conventional empirical treatment, assuming that administration of the antibiotics in a prolonged infusion would allow for a greater fT > MIC that will lead to a better efficacy.

These studies were carried out in different populations and there is only limited information about the importance of continuous infusion therapy in patients with hematologic diseases with neutropenic fever.

Research goals: The main goal is to compare between two groups of hematologic patients with neutropenic fever, The first group will receive antibiotic therapy in extended infusion, and the second (control) group will receive the treatment in a fixed time.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tel-Aviv Sourasky Medical Center
• Treatments: Anti-Bacterial Agents; Antibiotics, Antitubercular; Ceftazidime; Meropenem; Penicillanic Acid; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Thienamycins; Vancomycin

Criteria

Inclusion Criteria:

1. Patients who are able to sign an informed consent form

2. Hospitalized patients for one of the following reasons:

• Induction or consolidation for Acute Leukemia

• Patients Hospitalized for Autologous BMT

• Patients Hospitalized for Allogeneic BMT.

Exclusion Criteria:

1. Patients under the age of 18.

2. Patients who are unable to provide informed consent.

3. Patients with acute lymphatic leukemia hospitalized for maintenance treatment

4. Patients who will not be staying for the entire duration of neutropenia in house.